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Abstract
The HMG box transcription factor Sox9 plays a critical role in progenitor cell expansion during pancreas organogenesis and
is required for proper endocrine cell development in the embryo. Based on in vitro studies it has been suggested that Sox9
controls expression of a network of important developmental regulators, including Tcf2/MODY5, Hnf6, and Foxa2, in
pancreatic progenitor cells. Here, we sought to: 1) determine whether Sox9 regulates this transcriptional network in vivo and
2) investigate whether reduced Sox9 gene dosage leads to impaired glucose homeostasis in adult mice. Employing two
genetic models of temporally-controlled Sox9 inactivation in pancreatic progenitor cells, we demonstrate that contrary to in
vitro findings, Sox9 is not required for Tcf2, Hnf6, or Foxa2 expression in vivo. Moreover, our analysis revealed a novel role for
Sox9 in maintaining the expression of Pdx1/MODY4, which is an important transcriptional regulator of beta-cell
development. We further show that reduced beta-cell mass in Sox9-haploinsufficient mice leads to glucose intolerance
during adulthood. Sox9-haploinsufficient mice displayed 50% reduced beta-cell mass at birth, which recovered partially via a
compensatory increase in beta-cell proliferation early postnatally. Endocrine islets from mice with reduced Sox9 gene
dosage exhibited normal glucose stimulated insulin secretion. Our findings show Sox9 plays an important role in endocrine
development by maintaining Ngn3 and Pdx1 expression. Glucose intolerance in Sox9-haploinsufficient mice suggests that
mutations in Sox9 could play a role in diabetes in humans.
Citation: Dubois CL, Shih HP, Seymour PA, Patel NA, Behrmann JM, et al. (2011) Sox9-Haploinsufficiency Causes Glucose Intolerance in Mice. PLoS ONE 6(8):
e23131. doi:10.1371/journal.pone.0023131
Editor: Kathrin Maedler, University of Bremen, Germany
Received March 16, 2011; Accepted July 7, 2011; Published August 2, 2011
Copyright:  2011 Dubois et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the NIH/NIDDK (RO1 DK078803 and RO1 DK68471) to M.S., by postdoctoral fellowships from the JDRF to P.A.S.
and H.P.S., and a graduate student fellowship from the CIRM to C.L.D and N.A.P. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: masander@ucsd.edu
. These authors contributed equally to this work.
Introduction
Both proper neogenesis of mature endocrine cells during
embryonic pancreas development and the maintenance of an
adequate number of functional islets during adulthood are
necessary for normal glucose homeostasis. During development,
endocrine and exocrine (ductal and acinar) cells of the pancreas
derive from multipotent progenitor cells (MPCs) expressing the
transcription factors Pdx1 [1], Ptf1a [2], Sox9 [3] and Tcf2
(Hnf1b) [4]. Furthermore, all five endocrine cell types, including
the insulin
+ beta-cells, arise from a common transient endocrine
progenitor marked by expression of the transcription factor
Neurogenin 3 (Ngn3) [1]. Proper allocation of MPCs to the
endocrine lineage is achieved by induction of Ngn3 [5], which is
tightly governed by a complex transcriptional network involving
Notch signaling as well as transcription factors, such as Tcf2,
Foxa2 (Hnf3b), and Hnf6. While it is well established that Pdx1
(also known as maturity onset diabetes of the young [MODY] 4
[6,7,8]) is required for MPC specification as well as for proper
adult islet function [9,10,11], Pdx1 has also recently been shown to
regulate Ngn3 directly in cooperation with Hnf6 [12].
We have shown previously that the MPC marker and
maintenance factor Sox9 [3,13,14] governs endocrine development
in a dosage-dependent manner [14]. Pancreas-specific Sox9-
haploinsufficiency in Pdx1-Cre; Sox9
+/flox (Sox9
+/Dpan) mice results
in a 50% decrease in both Ngn3
+ endocrine progenitors and
consequently, endocrine cells at birth [14]. While reduced in
numbers, immunohistochemical analysis of beta-cell markers
suggested that beta-cells are properly differentiated in Sox9-
haploinsufficient mice. Though Sox9 has been shown to bind
the Ngn3 promoter in embryonic pancreas in vivo [14], in vitro
studies have implied that it also regulates Hnf6, Tcf2, and Foxa2
and is therefore critical for activating and/or maintaining an entire
network of endocrine differentiation genes [15]. However, because
early deletion of Sox9 in pancreatic progenitors results in
developmental arrest prior to the onset of endocrine cell
differentiation [13], the role of Sox9 in regulating key endocrine
differentiation genes in vivo has not been studied. By employing
temporally controlled Sox9 inactivation strategies in mice, we thus
sought to determine which components of the pancreatic
transcriptional network are regulated by Sox9 in vivo.
MODY is a disease caused by mutations in autosomal dominant
genes: MODY1–5 result from mutations in Hnf4a, glucokinase,
Hnf1a, Pdx1, and Tcf2, respectively. Most MODY genes are
expressed in the mature islet; their downregulation is associated
with loss of islet function, manifesting in diabetes [9,16,17,18].
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expression pattern of Sox9, it is expressed in the MPC population,
then confined to ductal and centroacinar cells in adult pancreas
[3,19]. Thus, MODY can occur not only as a result of mutations
in genes expressed in adult beta-cells, but also, due to mutations in
genes expressed in the progenitors from which they arise. Tcf2
exemplifies that defects in the embryonic development of beta-cells
can manifest in diabetes later in life. On the basis of the findings
that: 1) Sox9-haploinsufficient mice are born with half the normal
complement of pancreatic endocrine cells [14]; 2) Sox9 colocalizes
with Tcf2 in embryonic and adult pancreas [3], and 3) Sox9
regulates Tcf2 in vitro [15], we sought to explore whether reduced
Sox9 activity could result in a diabetic phenotype during
adulthood.
Here, we identify a novel role for Sox9 in the regulation of the
transcriptional network upstream of Ngn3, specifically in the
maintenance of Pdx1 (MODY4) expression. Contrary to previous
in vitro studies we find that Sox9 is dispensable for expression of
Tcf2, Hnf6, and Foxa2 in the developing pancreas. Additionally,
by characterizing the adult phenotype of Sox9-haploinsufficient
mice, we show that reduction of Sox9 gene dosage causes glucose
intolerance. Sox9-haploinsufficient mice did not progress to overt
diabetes, likely owing to a compensatory postnatal increase in




All animal experiments described herein were approved by the
University of California, Irvine and San Diego Institutional
Animal Care and Use Committees (protocol numbers 2001–
2420 and S08215, respectively).





generated and maintained as previously described [14]. Gt(RO-
SA)26Sor
tm1(cre/Esr1)Nat/J (hereon abbreviated to R26CreTM) mice
[20] were obtained from Jackson Laboratory (JAX) and main-
tained on a C57BL/6J background before breeding to Sox9
flox/flox
mice. In all experiments, Cre
2 littermates served as controls.
Embryos were harvested from timed matings in which noon on the
day of vaginal plug appearance was considered as e0.5. Sox9-




mice was induced by intraperitoneal (i.p.) injection of 3 mg/40 g
body weight tamoxifen (Sigma) dissolved in corn oil (Sigma) into
e12.5 or e14.5 pregnant dams. Since recombination in this system
occurs within 6 hours of tamoxifen administration [21,22],
R26CreTM; Sox9
flox/flox mice will be denoted as Sox9
De13/De13 or
Sox9
De15/De15, respectively. For BrdU labeling of 2-week-old mice,
50 mM BrdU (Sigma) was injected i.p. 6 hours before sacrifice. In
6-week-old mice, BrdU labeling was achieved by administration of
1 mg/mL BrdU in the drinking water for one week before
sacrifice. High-fat diet-fed mice were fed a 60% high-fat diet from
Bio-Serv (F3282).
Histological Analysis and Beta-Cell Mass Measurements
Tissue preparation, immunochemistry, imaging, and morpho-
metric analysis were performed as previously described [14]. Beta-
cell mass was calculated as follows: (insulin
+ area/total pancreatic
area) multiplied by pancreatic weight. For beta-cell proliferation
measurements, BrdU and insulin co-positive cells were counted
and expressed relative to total insulin
+ cells. A minimum of 50
islets were analyzed per animal. At least 3 mice were analyzed for
each experimental group.
The following primary antibodies were used at the given
dilutions: rabbit anti-Sox9 (Chemicon), 1:1000; goat anti-Sox9
(Santa Cruz), 1:100; guinea pig anti-Pdx1 (kindly provided by C. V.
E. Wright, Vanderbilt University, Nashville TN), 1:10,000; rabbit
anti-Hnf6 (Santa Cruz), 1:200; goat anti-Spp1 (R&D Systems),
1:1000; goat anti-Foxa2 (Santa Cruz), 1:200; goat anti-Tcf2 (Santa
Cruz), 1:100; rat anti-E-cadherin (Sigma), 1:1000; guinea pig anti-
insulin (DAKO), 1:1000; mouse anti-glucagon (DAKO), 1:10,000
and mouse anti-BrdU (Chemicon), 1:200. Secondary antibodies
were diluted 1:2000 (Jackson ImmunoResearch or Invitrogen).
Quantitative RT-PCR and Western Blot
At e15.5, RNA was extracted from pancreata of nine embryos
per experimental group and three pancreata per genotype were
pooled. Each PCR was run in triplicate. RNA isolation, cDNA
synthesis and quantitative (q)RT-PCR were performed and
analyzed as previously described [14].
Primers (59-39) used were: Sox9 forward: AGACTCA-
CATCTCTCCTAATGCT and reverse: ACGTCGGTTTTGG-
GAGTGG; Foxa2 forward: AGGCACTGCGCTTCACTCC and
reverse: CTCATTCCAGCGCCCACATAG; Ngn3 forward:
AATGATCGGGAGCGCAATCG and reverse: CGCAGGGT-
CTCGACCTTTG; Pdx1 forward: GATGAAATCCACCAAA-
GCTCA and reverse: AGAATTCCTTCTCCAGCTCCA; Hnf6
forward: GGCAACGTGAGCGGTAGTTT and reverse: TTG-
CTGGGAGTTGTGAATGC; Tcf2 forward: GCCTGAAC-
CAATCCCACCTC and reverse: TGACTGCTTTTGTCTGT-
CATGT.
Protein for Western blots was obtained, processed, transferred
to nitrocellulose, and incubated with primary antibody as
previously described [14]. Pancreata from 3 mice were pooled
per sample. Signal was detected and quantified using the Odyssey
infrared imaging system and reagents (LI-COR Technologies).
Values were calculated relative to GAPDH expression.
Metabolic Assays
Intraperitoneal glucose tolerance tests (IPGTTs) were per-
formed on mice after 16 hours of fasting. Mice were injected i.p.
with 1.5 mg/g body weight dextrose solution and their blood
glucose was measured at the outset as well as 20, 40, 60, 90, and
120 minutes post-challenge. For in vitro glucose stimulated insulin
secretion (GSIS) assays, islets were isolated as previously described
[14] and cultured overnight at 37uC in RPMI 1640 (Mediatech)
supplemented with 4.8 mM D-glucose (Fisher), 10 mM HEPES
(Sigma), 2 mM glutamine (Gibco), 1 mM sodium pyruvate
(Sigma), 10% FBS (Sigma) and 1% penicillin/streptomycin
(Mediatech). Sets of 30 islets were incubated in 500 ml KRBH
buffer [23] containing 2.8 mM D-glucose for 1 hour at 37uC.
Buffer was replaced with KRBH containing 16.7 mM D-glucose
for an additional 2-hour incubation. Buffer was collected and islets
were sonicated in acid ethanol. Insulin content was separately
determined in the supernatant and the islet cell fraction and the
percentage of secreted insulin calculated as: 100*(secreted insulin/
secreted insulin+islet cell insulin), as previously described [24].
Whole pancreas extracts were obtained by homogenizing whole
pancreata in acid ethanol, incubating overnight at 4uC, and
harvesting the supernatant. Serum was collected from the blood of
16-hour fasted mice. In all cases, insulin content was determined
by mouse insulin ELISA (ALPCO Diagnostics).
Statistical Analysis
All values are shown as mean 6 standard error of the mean
(S.E.M.); p values were calculated using unpaired two-tailed
Student’s t test; p,0.05 was considered significant.
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Sox9 expression parallels that of a network of factors
upstream of Ngn3
Previously, we showed that Sox9
+/Dpan embryos exhibit a 50%
reduction in the number of Ngn3
+ endocrine progenitors and
consequently, all mature endocrine cell types [14]. However, it
remains unclear why endocrine cells are reduced in Sox9
+/Dpan
embryos and how Sox9 orchestrates endocrine cell development in
conjunction with other transcriptional regulators that control
endocrine cell differentiation. It has been reported that Sox9
regulates the transcription factors Hnf6, Tcf2, and Foxa2, in the
mPAC pancreatic tumor cell line [15]. However, it has not been
studied whether Sox9 controls the expression of these endocrine
differentiation genes during development. Therefore, to test
whether this regulation occurs in vivo, we first examined whether
the expression domain of Sox9 coincides with those of these
transcription factors in MPCs.
At e12.5, when the pancreatic epithelium predominantly
comprises undifferentiated progenitors, Sox9 is widely co-
expressed with Pdx1 (Fig. 1A-A0). At this stage, Sox9
+ cells are
also intimately associated with cells expressing osteopontin (Spp-1),
which, like mucin-1, marks the apical aspect of cells lining the
forming luminal network within a still-stratified epithelium [25]
(Fig. 1B). Paralleling the expression domain of Sox9, Hnf6
similarly marks cells lining the Spp-1-delineated epithelial lumen
Figure 1. Sox9 is co-expressed with Hnf6, Foxa2, Tcf2, and Pdx1 in progenitor cords of the developing pancreas. Immunofluorescence
staining of e12.5 (A–D) and e15.5 (E–H) wild-type pancreata reveals extensive overlap of the Sox9
+ domain with Hnf6 (B, F), Foxa2 (C, G), and Tcf2
(D, H). (B, F) Osteopontin (Spp1), which marks the apical surface of cells in the lumen of the epithelial cords, is used as a reference for the Sox9 and
Hnf6 expression domains. (A) Sox9 is widely coexpressed with Pdx1 throughout the pancreatic epithelium at e12.5. Pdx1
+/Sox9
2 cells at this stage
are insulin/glucagon
+ (ins+glu) (A9-A0, white arrowheads). (E) At e15.5, Sox9
+ cells are found restricted to the inner epithelial layer and are weakly
Pdx1





2 cells producing insulin/glucagon are present at e12.5 (C9-C0, white arrowheads), as well as at e15.5 (G9-G0,
white arrowheads). (D) At e12.5, Sox9 and Tcf2 widely colocalize throughout the pancreatic epithelium. (H) By e15.5, some cells that are Sox9
+/Tcf2
2
are visible at the distal tips of the epithelial cords (H9-H0, white arrowheads). Scale bars: 50 mm.
doi:10.1371/journal.pone.0023131.g001
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(Fig. 1C-C0) and Tcf2 (Fig. 1D-D0). Some cells already
expressing glucagon and/or insulin with elevated Foxa2 levels
but little or no Sox9 were also present (Fig. 1C-C0).
By e15.5, during the major window of pancreatic differentiation
(termed the secondary transition), Sox9 becomes exclusively
restricted to the monolayered, polarized epithelial ‘‘cords’’
(Fig. 1E–H0), from which Ngn3
+ endocrine progenitors and their
descendents as well as mature ductal cells arise [3,4]. In the
progenitor epithelium, Sox9 co-localized with Pdx1 (Fig. 1E9,E0,
yellow arrowheads). Notably, Sox9
+ progenitors displayed lower
levels of Pdx1 expression than the Sox9
2 hormone
+-cells that have
delaminated from the progenitor cell epithelium (Fig. 1E9,E0,
yellow versus white arrowheads) [26]. Sox9
+ progenitors also
expressed Foxa2 at e15.5 (Fig. 1G-G0). As previously reported
[4], progenitor cells of the e15.5 epithelial cords were additionally
marked by Tcf2 (Fig. 1H). However, at the distal tips of the
lumens, we consistently observed cells that expressed high levels of
Sox9, but little or no Tcf2 (Fig. 1H9,H0, arrowheads). These
distal Sox9
+ cells presumably constitute acinar progenitors [3].
Together, this expression analysis shows that Sox9
+ progenitors
express Pdx1, Hnf6, Foxa2, and Tcf2 during the major period of
endocrine cell differentiation.
Sox9 is required for the maintenance of Pdx1
Next, we examined whether Sox9 regulates the expression of the
transcription factors Pdx1, Hnf6, Foxa2, and Tcf2 in the pancreatic
progenitor epithelium. We have shown that Pdx1-Cre-mediated
inactivation of both Sox9
flox alleles leads to pancreatic hypoplasia
(Fig. 2B,D,F,H,J; [13]). Although we saw no obvious decrease in
Pdx1 expression at e10.5 in Sox9
Dpan/Dpan pancreata [13], by e12.5,
there was a striking decrease in Pdx1 immunofluorescence intensity
in Sox9-deleted cells (Fig. 2C,D). In contrast to our earlier analysis
[13], some mosaicism was apparent in the deletion of Sox9 by Pdx1-
Cre. As such, robust Pdx1 expression was maintained only in those
progenitor cells that retained Sox9 (Fig. 2D, arrowheads).
Together, the retention of Pdx1 in Sox9
+ cells and the gradual
lossofPdx1 inSox9-deleted cellssuggest thatSox9is requiredforthe
maintenance of Pdx1 expression in pancreatic progenitors. Con-
trastingly, at e12.5, the expression of Hnf6, Foxa2, and Tcf2
appeared unaffected by Sox9 deletion (Fig. 2E–J).
It has been proposed that Sox9 interacts with Hnf6, Foxa2, and
Tcf2 in a transcriptional network that stabilizes pancreatic
progenitor gene expression, but also cooperates in activating
Ngn3, which disrupts the network in order to drive endocrine
differentiation [15]. To investigate whether Sox9 differentially
regulates these transcription factors during the major period of
endocrine cell neogenesis in vivo, we examined the expression of
Hnf6, Foxa2, and Tcf2, as well as Pdx1 in Sox9-deficient pancreas
at e15.5. However, the acute pancreatic hypoplasia resulting from
Pdx1-Cre-mediated Sox9 ablation precluded us from dissecting later
roles of Sox9 in pancreatic differentiation. To overcome this
obstacle, we utilized a ubiquitously expressed tamoxifen-inducible
Cre line, R26CreTM, to ablate Sox9 after e12.5 and then examine
the effects at e15.5 in Sox9
De13/De13 mice.
R26CreTM-mediated deletion of Sox9 by intraperitoneal admin-
istration of tamoxifen at e12.5 in pregnant dams resulted in
efficient ablation of Sox9 protein in ,90% of the luminal
epithelial cells comprising the Sox9
+ domain at e15.5 (Fig. 3A,B).
Since Sox9 was inactivated after the period of rapid progenitor cell
expansion, overall pancreatic organ size and morphogenesis were
not significantly affected in Sox9
De13/De13 mice at e15.5 (Fig. 3A–
J; data not shown). Mirroring our earlier observation of Pdx1
loss following Pdx1-Cre-mediated Sox9 deletion (Fig. 2C–D),
immunofluorescence analysis revealed a dramatic decrease in the
number of Pdx1
+ cells at e15.5 in Sox9
De13/De13 pancreata
(Fig. 3C,D). This decrease was predominantly observed in the
luminal epithelial cells and was accompanied by a marked
reduction in the number of newly-formed Pdx1
+/insulin
+ cells
(Fig. 3D). Since Pdx1 is critical for endocrine cell differentiation
and regulates expression of the endocrine differentiation factor
Ngn3 [12], this finding suggests that Sox9-dependent regulation of
Pdx1 expression in the progenitor cell epithelium after e13.5 is
critical for the major wave of beta-cell differentiation that occurs
between e14 and birth. While Sox9 deletion had a profound effect
on Pdx1 expression, the expression of Hnf6, Foxa2, and Tcf2
appeared unaffected by the loss of Sox9 (Fig. 3E–J). To determine
whether Sox9 might control the expression of Hnf6, Foxa2, Tcf2,
and Pdx1 at later time points, when Sox9 becomes restricted to the
pancreatic ducts (Fig. 3K), we induced Sox9 deletion by injecting
pregnant dams with tamoxifen at e14.5 and analyzed the embryos
at e18.5 in Sox9
De15/De15 mice. Similar to the inactivation
performed at e12.5, R26CreTM-mediated deletion of Sox9 by
tamoxifen injection at e14.5 resulted in efficient ablation of Sox9
protein (Fig. 3K,L). At e18.5, Pdx1 expression is largely restricted
to the endocrine cell compartment (Fig. 3M; [26]). Sox9 deletion
Figure 2. Pancreas-specific Sox9-deletion results in loss of Pdx1
by e12.5. Immunofluorescence staining of control (A, C, E, G, I) and
Sox9
Dpan/Dpan pancreata (B, D, F, H, J) at e12.5. Pdx1-Cre-mediated Sox9-
flox recombination efficiently ablates Sox9 (B), resulting in pancreatic
hypoplasia (B, D, F, H, J). (A, B, E–J) E-cadherin (Ecad) was used to
visualize the Sox9
2 pancreatic epithelium. While loss of Sox9 does not
affect expression of Hnf6 (F), Foxa2 (H), or Tcf2 (J), Pdx1 expression is
reduced (D). (D) Mosaic recombination results in an unrecombined
population of Sox9
+ cells, which retains high levels of Pdx1 (white
arrowheads). Scale bars: 50 mm.
doi:10.1371/journal.pone.0023131.g002
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+ cells, suggesting that
Sox9 continues to be required for endocrine cell formation at later
stages of development (Fig. 3N). This finding is consistent with the
observation that Sox9
+ cells give rise to new endocrine cells until
birth [3]. Mirroring our results obtained in embryos after Sox9
deletion at earlier time points, ablation of Sox9 during late
embryogenesis did not affect the expression of Hnf6, Foxa2, and
Tcf2 (Fig. 3O–T).
Quantitative RT-PCR analysis confirmed the requirement of
Sox9 for Pdx1 expression, revealing a significant, dose-dependent




De13/De13 mice at e15.5
(Fig. 4A). Likewise, and consistent with our findings in Sox9
+/Dpan
mice [14] (Fig. 4B), Ngn3 mRNA levels were dependent upon
Sox9 gene dosage (Fig. 4A,B). Reflecting the reduction in mRNA
levels, whole pancreata of e15.5 Sox9
De13/De13 mice also exhibited a
60% reduction in Pdx1 protein levels compared with those of
control littermates (Fig. 4C,D). Concordant with the results of our
immunofluorescence analysis (Fig. 3E–J), Hnf6, Foxa2, and Tcf2
transcript and protein levels at e15.5 were unaffected by deletion
of Sox9 at ,e13 (Fig. 4A,C,D). Unlike Sox9
+/De13 mice (Fig. 4A),
Sox9
+/Dpan mice displayed a slight, but significant reduction in Hnf6
and FoxA2 mRNA levels at e15.5 (Fig. 4B).
Our findings reveal that Sox9 is crucially required for
maintaining Pdx1 and Ngn3 expression in the pancreatic
progenitor cell epithelium during the major wave of endocrine
cell differentiation. Since Pdx1 has been shown to regulate the
expression of Ngn3 and, in turn, beta-cell formation [12], Sox9-
dependent regulation of Pdx1 is a critical component of the
transcriptional network governing endocrine and beta-cell devel-
opment. However, as Pdx1 levels are not affected by Sox9-
halpoinsufficiency, direct regulation of Ngn3 by Sox9 appears to be
the critical factor that accounts for reduced endocrine cell mass in
pancreata of Sox9-haploinsufficient mice at birth. Importantly, the
fact that Hnf6, Foxa2, and Tcf2 expression were not affected by
deletion of Sox9 argues strongly that, contrary to the in vitro findings
of Lynn et al. [15], Sox9 does not regulate these upstream
regulators of Ngn3 expression during pancreas organogenesis.
Figure 3. Sox9 deletion during endocrine cell neogenesis results in reduced numbers of Pdx1
+ cells. Immunofluorescence staining of
control (A, C, E, G, I, K, M, O, Q, S) and R26-CreER; Sox9
flox/fox embryos (B, D, F, H, J, L, N, P, E, T) injected with tamoxifen at e12.5 and analyzed at
e15.5 (Sox9
De13/De13) or injected with tamoxifen at e14.5 and analyzed at e18.5 (Sox9
De15/De15). Sox9 expression is lost in the majority of E-cadherin
+
(Ecad
+) epithelial cells (B, L). Deletion of Sox9 results in decreased expression of Pdx1 (D, N) as well as a reduction in the number of insulin
+ (Ins
+)
cells, while Hnf6 (F, P), FoxA2 (H, R), and Tcf2 (J, T) expression is unaffected. Scale bar: 50 mm.
doi:10.1371/journal.pone.0023131.g003
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Previous studies demonstrating that haploinsufficiency for
regulators of beta-cell development can manifest in MODY-type
diabetes [19,27] led us to next examine whether Sox9
+/Dpan mice
display a diabetic phenotype in adulthood. To ascertain the
physiological effects of pancreatic Sox9-haploinsufficiency in
adulthood, we monitored the body weight and blood glucose
levels of ad libitum-fed Sox9
+/Dpan and Cre
2 control mice over a 60-
week period. We found that, over the period of study, Sox9
+/Dpan
mice showed no difference in body weight (Fig. 5A), nor random-
fed blood glucose levels (Fig. 5B) compared to littermate controls.
However, while there was also no significant difference between
fasted blood glucose levels of Sox9
+/Dpan mice and control siblings,
Sox9
+/Dpan mice tended to exhibit higher blood glucose levels which
in time progressed to diabetic levels (.7 mmol/l in the fasted
state, as indicated by the broken line; Fig. 5C). Consistent with
developing glucose intolerance, by six weeks of age, blood glucose
levels were significantly elevated in Sox9
+/Dpan mice compared with
control littermates following an acute glucose challenge (Fig. 5D).
Glucose intolerance persisted in Sox9
+/Dpan mice at 12 weeks of age
and later time points (Fig. 5E,F).
In order to confirm that the glucose intolerance observed in Pdx1-
Cre; Sox9
+/flox versus Sox9
+/flox control mice was not attributable to
extraneous effects of the Pdx1-Cre transgene as reported in the RIP-Cre
mouse line [28], we assayed glucose tolerance in Pdx1-Cre versus wild-
type siblings on a Sox9
+/+ background. The absence of any difference
in blood glucose levels between the two genotypes in response to a
glucose challenge (Fig. 5G) shows that the Pdx1-Cre transgene itself
exerts no influence on glucose tolerance in the current studies. Thus,
pancreatic Sox9-haploinsufficiency results in glucose intolerance.
High-fat diet causes fasting hyperglycemia in
Sox9-haploinsufficient mice
Though the endocrine function of the reduced beta-cell
complement in Sox9
+/Dpan pancreata was sufficiently high to
maintain normogycemia under basal conditions, we postulated
that Sox9-haploinsufficiency might impair the ability to withstand
additional metabolic stress. To test this, we maintained Sox9
+/Dpan
and littermate control mice on a 60% high-fat diet and monitored
body weight and ad libitum fed blood glucose levels. Throughout
the course of one year on this diet, no significant difference was
detected in either body weight or blood glucose levels between
Sox9-haploinsufficient and control siblings (Fig. 6A,B). However,
fasting blood glucose levels in Sox9
+/Dpan mice were significantly
elevated over those of control animals, attaining levels considered
diabetic (Fig. 6C). Concordantly, when high-fat diet-fed mice
were subjected to intraperitoneal glucose challenge, Sox9
+/Dpan
mice displayed significantly elevated blood glucose levels over
those of control littermates (Fig. 6D), mirroring the findings in
normal diet-fed Sox9
+/Dpan mice. Thus, the additional metabolic
demand/stress of a high-fat diet mildly exacerbated the metabolic
defect resulting from pancreatic Sox9-haploinsufficiency.
Compensatory postnatal beta-cell proliferation in
Sox9-haploinsufficient mice
Given that heterozygous pancreatic deletion of Sox9 results in a
two-fold decrease in beta-cell mass at birth [14], we were surprised
Figure 4. Sox9 regulates Pdx1 mRNA and protein expression. Quantitative RT-PCR of pancreata from Sox9
flox/fox or Sox9
+/fox embryos injected
with tamoxifen at e12.5 and analyzed at e15.5 (Sox9
De13/De13 or Sox9
+/De13)( A; n=9) shows reduced levels of Pdx1 and Ngn3, but not of Hnf6, FoxA2,o r
Tcf2.I nSox9
+/Dpan pancreata after Pdx1-Cre-mediated recombination of one Sox9-flox allele (B; n=9), Pdx1, Ngn3, Hnf6, and FoxA2 mRNA levels are
reduced at e15.5. Western Blot analysis (C, D; n=4) shows diminished Pdx1 expression, but not Hnf6, Foxa2, or Tcf2 expression in pancreata from
Sox9
De13/De13 embryos at e15.5. Values are shown as mean 6 S.E.M.; *=P,0.05; **=P,0.01.
doi:10.1371/journal.pone.0023131.g004
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23131Figure 5. Sox9-haploinsufficient mice are glucose-intolerant. Body weight (A), random fed blood glucose levels (B), and fasting blood glucose
levels (C) do not significantly differ in Sox9
+/Dpan and control mice (n=10), except for fasting blood glucose levels in Sox9
+/Dpan mice at 36 weeks of
age. (C) The dashed line indicates the threshold at which blood glucose levels are considered diabetic. Following an intraperitoneal glucose
challenge, Sox9
+/Dpan mice exhibit elevated blood glucose levels compared to control mice at 6 weeks (D; n=20), 12 weeks (E; n=18), and 36 weeks
(F; n=8) of age. (G) Blood glucose levels in response to an intraperitoneal glucose challenge are similar in Pdx1-Cre mice and wild-type littermates
(n=11). Values are shown as mean 6 S.E.M.; *=P,0.05; **=P,0.01.
doi:10.1371/journal.pone.0023131.g005
Sox9-Haploinsufficiency Causes Glucose Intolerance
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23131to find that glucose homeostasis in these mice was only mildly
impaired. Therefore, we sought to characterize how Sox9-
haploinsufficient mice lacking half the usual complement of
beta-cells are able to remain relatively normoglycemic, even with
age and under increased metabolic stress.
Immunofluorescence analysis revealed that at six weeks of age,
while smaller than those of their control siblings, islets of Sox9
+/Dpan
mice displayed normal cytoarchitecture, with a central core of
insulin
+ beta-cells surrounded by a mantle composed primarily of
glucagon
+ alpha-cells (Fig. 7A). Concordantly, islets isolated from
Sox9-haploinsufficient mice exhibited normal insulin secretion
when stimulated with glucose in vitro (Fig. 7B). We have previously
reported that at e18.5, beta-cell mass in Sox9
+/Dpan mice was 50%
reduced compared to control mice [14]. However, by six weeks of
age, beta-cell mass in Sox9 heterozygous mutant mice had risen to
68% that of control littermates, an increase that was maintained at
16 weeks of age (Fig. 7C). Consistent with our morphometric
data, total pancreatic insulin content in six-week-old Sox9
+/Dpan
mice was 70% that in control animals (Fig. 7D). Fasting serum
insulin levels in Sox9-haploinsufficient mice were not significantly
different from those of controls (Fig. 7E).
The increase in beta-cell mass from 50% to 68% of control mice
between e18.5 and six weeks of age suggested that beta-cells of
Sox9
+/Dpan mice were capable of adaptive expansion to maintain
normoglycemia. This inference was also supported by the fact that
these mice did not become overtly diabetic even when metabol-
ically stressed via maintenance on a high-fat diet. To determine
how and when this increase in beta-cell mass occurred, we
measured the proliferation rate of beta-cells in Sox9
+/Dpan mice by
assaying for BrdU incorporation at the age of two weeks, which is
a dynamic period of islet remodeling and growth in rodents
[29,30]. This analysis revealed that the beta-cell BrdU labeling
index in Sox9
+/Dpan mice was twice that in littermate controls,
although by six weeks of age, proliferation rates returned to
baseline levels (Fig. 7F,G). This is consistent with there being no
further adaptive increase in beta-cell mass in Sox9-haploinsufficient
mice beyond six weeks (Fig. 7C). Together, our data suggest that
while Sox9-haploinsufficiency results in a reduced beta-cell
complement, adaptive expansion of the beta-cell mass occurs




Sox9 as a critical regulator of the endocrine
differentiation program
As we reported previously [14], Sox9-haploinsufficiency leads to
a 50% decrease in the numbers of both Ngn3
+ progenitors and the
mature endocrine cells they give rise to. Studies by Lynn et al. [15]
in the pancreatic ductal mPAC cell line suggested that in addition
Figure 6. High-fat diet induces fasting hyperglycemia in Sox9-haploinsufficient mice. Sox9
+/Dpan mice and control littermates were fed a
60% high-fat diet over 50 weeks. Body weight (A) and random fed blood glucose levels (B) do not significantly differ in Sox9
+/Dpan and control mice
(n=14). (C) Fasting blood glucose levels are significantly higher in Sox9
+/Dpan than control mice (n=14). The dashed line indicates the threshold at
which blood glucose levels are considered diabetic. (D) Following an intraperitoneal glucose challenge, Sox9
+/Dpan mice exhibit elevated blood
glucose levels compared to control mice (n=14). Values are shown as mean 6 S.E.M.; *=P,0.05.
doi:10.1371/journal.pone.0023131.g006
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factors upstream of Ngn3, including Hnf6, Foxa2, and Tcf2. These
findings, reviewed most recently by Pan and Wright [31], while
intriguing, demanded further validation in an in vivo model. Our
finding that neither Hnf6, Foxa2 nor Tcf2 are dysregulated in the
embryonic pancreas following Sox9 ablation suggests that this same
transcriptional network is not conserved in pancreatic progenitor
cells in vivo.
Our in vivo findings suggest a revised model of the regulatory
interactions between key developmental transcription factors in
pancreatic progenitor cells (Fig. 8). Importantly, our study
uncovers a previously unknown role for Sox9 in regulating Pdx1
expression during the major time window of endocrine cell
differentiated in mice. Whether or not Sox9 regulates Pdx1
expression directly is currently unclear. In the early pancreatic
bud, Pdx1 expression is initially maintained upon Sox9 inactivation
in vivo [13] and only lost at e12.5, which argues against a role for
Sox9 in directly regulating Pdx1 at early pancreatic stages.
However, it is possible that Sox9 controls Pdx1 expression at early
and later developmental stages by distinct mechanisms and that
Sox9 deletion after e13 has a more immediate effect on Pdx1
expression. Pdx1 gene transcription is controlled by different
Figure 7. Sox9
+/Dpan mice exhibit compensatory postnatal beta-cell proliferation. (A) Immunofluorescence staining of control and
Sox9
+/Dpan pancreata for insulin and glucagon reveals normal islet architecture in Sox9
+/Dpan mice. (B) Normal glucose stimulated insulin secretion of
isolated islets from Sox9
+/Dpan mice (B; n=7). (C)I nSox9
+/Dpan mice, beta-cell mass is reduced by ,30% compared to control littermates at 6 and 16
weeks of age (n=3), consistent with pancreatic insulin content in 6-week-old Sox9
+/Dpan mice being 70% that of control siblings (D; n=11). (E) Serum
insulin levels are comparable in Sox9
+/Dpan mice and control littermates (n=11). (F, G) Beta-cell proliferation, measured by BrdU incorporation into
insulin
+ (Ins
+) cells, is increased in Sox9
+/Dpan mice at 2 weeks, but not at 6 weeks of age (n=3). Scale bars: 50 mm. Values are shown as mean 6 S.E.M.;
*=P,0.05.
doi:10.1371/journal.pone.0023131.g007
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transcription factors might dynamically change during develop-
ment. Genome wide DNA occupancy studies for Sox9 in
progenitor cells will determine which of the genes that are
regulated by Sox9 in vivo are direct transcriptional target genes.
Genetic studies have previously shown that similar to Sox9,
Hnf6 also functions upstream of Pdx1 [33] and is important for the
expression of Ngn3 [34]. Furthermore, Hnf6 has been shown to
regulate the expression of Tcf2 (MODY5) [19], a transcription
factor that is also required for Ngn3 expression [35]. We show that
even though all three factors are co-expressed in the epithelial
progenitor cords during the major wave of endocrine cell
formation, loss of Sox9 does not affect the expression of Tcf2 or
Hnf6. This suggests that Sox9 regulates Pdx1 and Ngn3 expression
independent of Tcf2 and Hnf6.
While the requirement for Ngn3 in endocrine development is
well established, the network of transcription factors required for
its activation has not been comprehensively identified, nor their
interactions clearly defined. Here, we reveal that Sox9 is required
for proper Ngn3 induction through several possible mechanisms.
Previous observations led us to suggest a mechanism through
which Sox9 induces Ngn3 expression. Wang et al. have recently
shown that Ngn3 expression in pancreatic progenitors must attain
a critical high ‘‘Ngn3
Hi’’ threshold level to initiate an endocrine
developmental program in those cells [36]. It is conceivable that
Sox9 activates Ngn3 in a dosage-sensitive manner such that a
Sox9
Hi expression level is crucial for activation of a Ngn3
Hi
expression level sufficient to induce endocrine differentiation. In
support of this hypothesis, we observed a significant reduction in
the number of Ngn3
Hi cells in Sox9-haploinsufficient mice [14].
Additionally, Pdx1, which we show is expressed in a Sox9-
dependent manner, has also been reported to activate Ngn3 in
coordination with Hnf6 [12]. Thus, Sox9 contributes to
acquisition of the Ngn3
Hi state by two mechanisms: (1) by directly
activating Ngn3 and (2) by reinforcing Ngn3 expression through
positive regulation of Pdx1. Since no functional role has thus far
been demonstrated for Sox9 in endocrine cell maturation [14],
those progenitors that attain sufficiently high Ngn3 expression to
initiate an endocrine program should differentiate normally, so
that, albeit reduced in numbers, the adult beta-cells of Sox9-
haploinsufficient pancreata are mature and fully functional.
Consistent with this notion, we found that islets from Sox9-
haploinsufficient mice exhibit normal GSIS in vitro.
The role of Sox9 in maintaining adult glucose
homeostasis
In humans, Sox9-haploinsufficiency is associated with the
syndrome campomelic dysplasia (CD). Although pancreatic islet
abnormalities have been reported in neonatal CD cases [37], the
early lethality of the condition precludes the manifestation of
metabolic defects. However, as pancreas-specific expression of
Sox9 is governed by enhancer region E1, located approximately
28 kb 59 of the transcription initiation site in humans [38], it is
conceivable that enhancer-specific Sox9 mutations could cause a
diabetic phenotype in humans. The viability of mice displaying
pancreas-specific heterozygous loss of Sox9 afforded us the unique
opportunity of studying the effects of reduced Sox9 dosage on
pancreatic endocrine function in adult mice, to test whether Sox9 is
a potential MODY or diabetes susceptibility gene.
While the majority of MODY genes play important functional
roles in adult beta-cells [16,17,27,39,40], Tcf2/MODY5 is the
exception. Like Sox9, Tcf2 is excluded from beta-cells and instead,
is expressed in the pancreatic progenitor epithelium during
embryonic development, becoming restricted to duct and
centroacinar cells in adulthood [3,4]. Pancreatic hypoplasia,
pancreatic atrophy, defective expression of Glut2, and impaired
insulin secretion have been reported in human cases of Tcf2
mutation [35,41]. This suggests that dysregulation of factors not
expressed in beta-cells but expressed in their precursors, can cause
diabetes independently of beta-cell dysfunction, due presumably to
pancreatic endocrine dysgenesis. While we found no evidence for
pancreatic Tcf2 expression being Sox9-dependent, our data
suggest that Sox9-haploinsufficiency might itself manifest in a
MODY phenotype. Furthermore, the fact that Sox9 regulates
expression of the MODY4 gene Pdx1 during development raises
the possibility that the diabetic phenotype caused by heterozygous
Pdx1 mutations [7] could in part be attributable to impaired beta-
cell development.
While we found a 50% reduction in Sox9 gene dosage to cause
glucose intolerance in mice, Sox9
+/Dpan mice did not develop overt
diabetes. This raises the question of how severely reduced
pancreatic Sox9 levels might affect glucose homeostasis in humans.
Interestingly, attempts to generate mouse models for human
MODY have revealed that mutations in mouse homologues of
human MODY genes do not always phenocopy the human
condition. While Tcf2-haploinsufficient humans display diabetes
and severe pancreatic endocrine defects [42,43], partially mirroring
ourfindings inSox9
+/Dpan mice, Tcf2
+/2 micedo notdisplay diabetic
symptoms [44]. Additionally, the MODY3 phenotype is not
recapitulated in Hnf1a
+/2 mice, although Hnf1a
2/2 mice do
become diabetic [17]. One possible explanation for the discrepancy
between the metabolic effects of MODY gene mutations in mouse
and humans is that the beta-cells of mice are able to better
compensate for the reduction in gene dosage than those of humans.
Consistent with this idea, we observed compensatory beta-cell
proliferation in Sox9
+/Dpan mice, which led to a significant, albeit not
complete, recovery of beta-cell mass during the early postnatal
period. Because human beta-cells have a much lower proliferative
capacity than murine beta-cells [45], it is predicted that reduced
Sox9 levels in humans will have more profound effects on glucose
homeostasis than observed in Sox9-haploinsufficient mice. Although
to this point Sox9 has not emerged as a type 2 diabetes susceptibility
gene from genome-wide association studies (GWAS) [46], other
genes with known roles in human diabetes, such as Pdx1, also failed
to show an association with type 2 diabetes in GWAS. Additional
studies are therefore required to determine whether mutations in
Sox9 are associated with diabetes in humans.
Figure 8. Contrasting the previously suggested Sox9 transcrip-
tional regulatory network during pancreas development to the
network based on genetic evidence. (A) Proposed Sox9 regulated
genes based on in vitro evidence [15]. (B) Revised model based on this
study as well as previous genetic in vivo studies [12,19,33,34,35,47].
Note that a solid line and arrow does not necessarily indicate direct
gene regulation.
doi:10.1371/journal.pone.0023131.g008
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